Related Experiment Video
Updated: Jul 31, 2026

Assembly and Purification of Prototype Foamy Virus Intasomes
Published on: March 19, 2018
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
S H Chao1, K Fujinaga, J E Marion
1Molecular Biology Program and the Department of Biochemistry, University of Iowa, Iowa City, Iowa 52242, USA.
Abstract:
Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clinical trials as a cancer treatment because of its antiproliferative properties. We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb. The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a K(i) of 3 nm. Interestingly, the drug was not competitive with ATP. P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat. Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro. Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC(50) of less than 10 nm.
Insights
Flavopiridol effectively inhibits RNA polymerase II transcription and HIV-1 replication by targeting P-TEFb. This cyclin-dependent kinase inhibitor shows potent antiviral and antiproliferative activity in vitro.
Area of Science:
- Molecular Biology
- Virology
- Pharmacology
Background:
- Flavopiridol is a cyclin-dependent kinase (Cdk) inhibitor investigated for cancer treatment due to its antiproliferative effects.
- Transcription by RNA polymerase II is a critical process regulated by factors like P-TEFb.
Purpose of the Study:
- To investigate the mechanism by which flavopiridol inhibits transcription.
- To evaluate the effect of flavopiridol on human immunodeficiency virus type 1 (HIV-1) replication.
Main Methods:
- In vitro transcription assays using RNA polymerase II.
- Enzyme inhibition studies to determine the binding kinetics of flavopiridol to P-TEFb.
- HIV-1 replication assays (single-round and viral spread).
Main Results:
- Flavopiridol potently inhibited RNA polymerase II transcription by blocking the transition to productive elongation, a step mediated by P-TEFb.
- The drug inhibited P-TEFb's ability to phosphorylate the RNA polymerase II carboxyl-terminal domain with a K(i) of 3 nm, non-competitively with ATP.
- Flavopiridol blocked Tat transactivation of the HIV-1 promoter and inhibited HIV-1 replication with an IC(50) < 10 nm.
Conclusions:
- Flavopiridol is a potent inhibitor of P-TEFb and RNA polymerase II transcription.
- Flavopiridol demonstrates significant antiviral activity against HIV-1 by inhibiting viral replication.
More Related Videos
07:22A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly